Search Results for “immune” – Page 81 – media

Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

Merck & Company is driving forward in its quest to develop a premier immuno-oncology pipeline. The company plunked down $394 million to acquire Australia-based Viralytics Ltd and its oncolytic immunotherapy treatments.
- Source: Biospace;
- 726
- February 26, 2018
immuno-oncology pipelin immunotherapy Market Views Merk
EKGs May Determine Major Depression or Bipolar Disorder

A groundbreaking Loyola Medicine study suggests that a simple 15-minute electrocardiogram could help a physician determine whether a patient has major depression or bipolar disorder.
- Source: bphope
- 625
- February 14, 2018
bipolar disorder Depression Researches
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The updated label includes Cosentyx data in moderate to severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which affects approximately half of all psoriasis patients.1-3 The label update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.6
- Source: pharma.us.novartis
- 551
- February 13, 2018
Cosentyx® FDA New Approvals Scalp psoriasis
NHS tells doctors to order stronger vaccine for next winter

England is not alone in being particularly hard hit this flu season, with Australia suffering its worst flu season in two decades and the US now grappling with a severe flu outbreak.
- Source: pharmafile
- 620
- February 8, 2018
flu outbreak NHS polices QIV
AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application (sNDA) for Feraheme® (ferumoxytol injection)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has approved its application to broaden the existing label for Feraheme® (ferumoxytol injection) beyond the current chronic kidney disease (CKD) indication to include all eligible adult Iron Deficiency Anemia (IDA) patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
- Source: Amagpharma
- 693
- February 8, 2018
chronic kidney disease FDA Feraheme New Approvals
Scientists see positive results from 1st ever gene editing therapy

A second patient has been treated in a historic gene editing study in California, and no major side effects or safety issues have emerged from the first man’s treatment nearly three months ago, doctors revealed Tuesday.
- Source: NYPost
- 498
- February 7, 2018
gene editing Gene therapy New Approvals
Ultrasound tech genetically controls cells to kill cancer new study finds

Researchers say the approach breaks new ground in treating cancer non-invasively and with unprecedented precision.
- Source: Healthcare IT news
- 583
- February 6, 2018
cancer CAR–T immunotherapy Researches
Enzychem Lifesciences Announces the FDA Orphan Drug Designation Granted to EC-18 on Acute Radiation Syndrome (ARS)

Enzychem Lifesciences, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to EC-18 for the treatment of Acute Radiation Syndrome (ARS).
- Source: china-pharmacy
- 597
- February 1, 2018
ARS EC-18 FDA Orphan Drug Designation rare diseases
Russian researchers develop test strip to diagnose heart attack

Scientists at the National University of Science and Technology (NUST) MISIS in Russia have developed a new membrane test strip for quantitative immune chromatography rapid tests to rapidly and accurately detect an acute myocardial infarction by analysing blood for the presence of disease markers.
- Source: medicaldevice-network
- 540
- January 31, 2018
immune chromatography rapid test Researches
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that a development milestone for cabiralizumab has been achieved, triggering a $25 million payment from Bristol-Myers Squibb Company (BMS) (BMY) under the license and collaboration agreement between the companies established in 2015. The milestone was triggered by initiation of a multi-arm Phase 2 clinical trial (NCT03336216), sponsored by Bristol-Myers Squibb Company, evaluating cabiralizumab and Opdivo® (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. “Effective treatment for patients with pancreatic cancer remains a significant unmet need and is a cancer for which existing immunotherapies have not been successful to date,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “We are encouraged by the preliminary data presented at SITC 2017 and are pleased to see this trial underway.” The Phase 2 trial is expected to enroll approximately 160 ...
- Source: finance.yahoo
- 552
- January 31, 2018
Bristol-Myers Squibb cabiralizumab Opdivo

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.